|Dr. John M. Maraganore||CEO & Exec. Director||1.12M||4.86M||1963|
|Mr. Barry E. Greene||Pres||775.15k||1.95M||1963|
|Mr. John K. Clarke||Founder & Director||60k||N/A||1954|
|Dr. Phillip A. Sharp||Co-Founder, Director & Member of the Scientific Advisory Board||90k||N/A||1945|
|Yvonne Greenstreet||Chief Operating Officer and Exec. VP||340.61k||N/A||1963|
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia. Its clinical programs also include ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR, which is in the Phase I clinical trial for the treatment of various forms of ATTR amyloidosis; Lumasiran (ALN-GO1) that is in Phase I/II clinical trial for the treatment of primary hyperoxaluria type 1; and Cemdisiran (ALN-CC5), which is in the Phase II clinical trial for the treatment of complement-mediated diseases. The company has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc; and Regeneron Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Alnylam Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2018 is 4. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 6; Compensation: 6.